Globenewswire·2025-10-01 21:10Core Viewpoint - Rosen Law Firm is reminding purchasers of Cytokinetics, Inc. common stock of the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements about the company's New Drug Application process for aficamten [1][5]. Group 1: Class Action Details - The class period for the lawsuit is from December 27, 2023, to May 6, 2025, and the lead plaintiff deadline is November 17, 2025 [1]. - Investors who purchased Cytokinetics common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time and has consistently ranked highly in securities class action settlements [4]. Group 3: Case Specifics - The lawsuit alleges that Cytokinetics made false and misleading statements regarding the timeline for the NDA submission and approval process for aficamten, specifically regarding expected FDA approval in the second half of 2025 [5]. - The company failed to disclose material risks related to the submission of a Risk Evaluation and Mitigation Strategy, which could delay the regulatory process, leading to investor damages when the true details were revealed [5].